NCT00068432View on ClinicalTrials.gov

Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

December 31, 2003

Primary Completion Date

July 31, 2005

Study Completion Date

July 31, 2005

Conditions
Pancreatic Cancer
Interventions
DRUG

Celecoxib

Oral celecoxib twice daily on days 1-28. Courses repeat every 4 weeks.

DRUG

Gemcitabine Hydrochloride

Receive gemcitabine by vein (IV) over 65 minutes on days 1, 8 and 15. Courses repeat every 4 weeks.

Trial Locations (11)

45429

CCOP - Dayton, Dayton

53405

All Saints Cancer Center at All Saints Healthcare, Racine

61801

CCOP - Carle Cancer Center, Urbana

64131

CCOP - Kansas City, Kansas City

65807

CCOP - Cancer Research for the Ozarks, Springfield

72913

Hembree Mercy Cancer Center at St. Edward Mercy Medical Center, Fort Smith

97225

CCOP - Columbia River Oncology Program, Portland

32806-2134

M.D. Anderson Cancer Center - Orlando, Orlando

30342-1701

CCOP - Atlanta Regional, Atlanta

67214-3882

CCOP - Wichita, Wichita

77030-4009

M.D. Anderson Cancer Center at University of Texas, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT00068432 - Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer | Biotech Hunter | Biotech Hunter